灵康药业(603669) - 2025 Q2 - 季度业绩预告

Current Period Performance Forecast The company forecasts a net loss for H1 2025, with attributable net profit between -39.5 million CNY and -35.0 million CNY, and operating revenue from 160 million CNY to 200 million CNY Estimated Financial Performance for H1 2025 | Metric | Estimated Amount (million CNY) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -39.5 to -35.0 | | Net Profit Attributable to Parent Company Shareholders (Excluding Non-Recurring Items) | -48.5 to -44.0 | | Operating Revenue | 160 to 200 | | Operating Revenue (After Deductions) | 153.4 to 193.4 | - The performance forecast data for this period has not been audited by a certified public accountant[4] Prior Period Performance Comparison Compared to the same period in 2024, the company's estimated net loss for H1 2025 has narrowed, with 2024 H1 net profit attributable to shareholders at -40.40 million CNY and non-recurring adjusted net profit at -54.42 million CNY Comparative Performance: H1 2025 Forecast vs. H1 2024 Actual | Metric | 2025 H1 Forecast (million CNY) | 2024 H1 Actual (million CNY) | | :--- | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -39.5 to -35.0 | -40.40 | | Net Profit Attributable to Parent Company Shareholders (Excluding Non-Recurring Items) | -48.5 to -44.0 | -54.42 | - Earnings per share for the same period last year was -0.06 CNY[6] Reasons for Forecasted Loss and Countermeasures The primary reason for the forecasted loss is insufficient sales gross profit to cover period expenses; the company is implementing strategies including promoting centralized procurement products, leveraging channel advantages for non-centralized procurement products, and expanding pharmaceutical distribution business - The primary reason for the current period's loss is that sales gross profit cannot cover period expenses[7] - Company countermeasures include: - Increasing promotion efforts for products winning centralized procurement bids - Leveraging channel advantages for market promotion of non-centralized procurement products - Expanding pharmaceutical distribution business to enhance company scale and strength[7] Risk Warning The company explicitly states that the performance forecast data is a preliminary internal calculation and has not been audited by a certified public accountant, thus the final results may differ - This performance forecast represents preliminary calculations by the company's finance department based on professional judgment and has not yet been audited by a certified public accountant[8] - The company believes there are no significant uncertainties that could affect the accuracy of this performance forecast[8] Other Explanations The company advises investors that the disclosed data is preliminary, and the final accurate financial figures will be based on the officially released 2025 semi-annual report, urging caution regarding investment risks - The forecast data provided above is preliminary, and the final accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report[9]